{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Clinical Benefit Response (sCR+CR+VGPR+PR+MR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Very Good Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Minimal Response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"}],"units":"Participants"}],"description":"sCR, CR, VGPR, PR, and minimal response (MR)","groups":[{"description":"Subjects will receive carfilzomib 20 mg/m2 intravenously on Days 1, 2, 8, 9, 15, and 16 of 28 day cycle.\n\nAssessed by principal investigator.","id":"OG000","title":"Carfilzomib (A0)"}],"paramType":"NUMBER","populationDescription":"Response-evaluable Population: Enrolled patients who completed at least 1 cycle of carfilzomib and who underwent disease assessments at Screening, Cycle 1 Day 15, and Cycle 2 Day 24. This analysis set also included patients who discontinued treatment during this time due to an AE that was considered probably related to carfilzomib.","reportingStatus":"POSTED","timeFrame":"Response assessments same as described in primary outcome measure","title":"Clinical Benefit Response (CBR) (A0 Only)","type":"SECONDARY","unitOfMeasure":"participants"}